Research > ETFs > ETF / ETP Commentary > 

Beyond Corporate Bonds: Enhance Income With Private Credit

  • Related Symbols
  • PCR
In the current higher-for-longer interest rate regime, more fixed income investors are seeking alternate paths to diversify their income sources. One option that may not have yet considered is private credit or more specifically, the Simplify Private Credit Strategy ETF (PCR) .PCR offers a compelling alternative or complement to traditional corporate bonds by providing institutional-grade private credit exposure within an ETF wrapper. Of course, there’s also its distribution rate of 11.48% (as of May 31, 2026), which will appease income seekers.Key Takeaways: PCR offers institutional-grade exposure within a liquid ETF wrapper, sporting an 11.48% distribution rate for income-focused investors. The fund primarily invests in business development companies and closed-end funds that hold floating-rate senior secured loans, allowing its coupon payouts to adjust alongside benchmark rates like SOFR. By utilizing total return swaps to replicate the VettaFi Private Credit Index, PCR bypasses the heavy duration risk of corporate bonds while capturing a significant yield premium in high-interest rate environments. See More: Private Credit Sees Rise in Acceptance For DC Plan PortfoliosBenefits of Private CreditTightening spreads make corporate bonds an enticing option, but private credit has inherent benefits that also make it worth a closer look. Corporate bonds are highly sensitive to duration and interest rate volatility so they can be subjected to the actions of the U.S. Federal Reserve’s monetary policy. Alternatively, the underlying holdings in PCR are primarily Business Development Companies (BDCs) and closed-end funds, which utilize floating-rate senior secured loans that can adapt to the Fed’s interest rate policy. As a result of this BDC and closed-end fund exposure, these coupons reset alongside benchmarks like the Secured Overnight Financing Rate (SOFR). That said, the fund an mitigate interest rate sensitivity and capture wider spreads, making it particularly resilient in “higher-for-longer” rate environments. Furthermore, PCR offers a significant yield premium over standard corporate bond benchmarks, providing an attractive path for income-focused investors to preserve purchasing power against persistent inflation.Systematically Active FlexibilityThe goal of PCR is to generate income and capital appreciation by investing the majority of its net assets in securities found within the VettaFi Private Credit Index. To achieve its investment objective, PCR invests in total return swaps linked to the constituents found within the index. The index specifically tracks private credit instruments held by publicly traded U.S. business development companies and closed-end funds that allocate over 50% of their portfolios to non-publicly traded corporate loans, syndicated debt, or high-yield bonds. PCR gives investors exposure to private credit with the accessibility, liquidity, and cost efficiency of an ETF wrapper. For more news, information, and analysis, visit the Institutional Income Strategies Content Hub. VettaFi LLC (“VettaFi”) is the index provider for PCR, for which it receives an index licensing fee. However, PCR is not issued, sponsored, endorsed, or sold by VettaFi, and VettaFi has no obligation or liability in connection with the issuance, administration, marketing, or trading of PCR.

Performance data shown is past performance and is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore you have a gain or loss when you sell your shares. For standard quarterly performance, go to the fund's Snapshot page by clicking on the ETF/ETP's symbol.

ETFs may trade at a premium or discount to their NAV and are subject to the market fluctuations of their underlying investments.

For iShares ETFs, Fidelity receives compensation from the ETF sponsor and/or its affiliates in connection with an exclusive long-term marketing program that includes promotion of iShares ETFs and inclusion of iShares funds in certain FBS platforms and investment programs. Please note, this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral. Additional information about the sources, amounts, and terms of compensation can be found in the ETF's prospectus and related documents. Fidelity may add or waive commissions on ETFs without prior notice. BlackRock and iShares are registered trademarks of BlackRock, Inc. and its affiliates.

FBS receives compensation from the fund's advisor or its affiliates in connection with a marketing program that includes the promotion of this security and other ETFs to customers ("Marketing Program"). The Marketing Program creates incentives for FBS to encourage the purchase of certain ETFs. Additional information about the sources, amounts, and terms of compensation is in the ETF's prospectus and related documents. Please note that this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral.

News, commentary (including "Related Symbols") and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended to help self-directed investors evaluate exchange traded products (ETPs), including, but limited to exchange traded funds (ETFs) and exchange traded notes (ETNs). Criteria and inputs entered, including the choice to make ETP comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a particular security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating ETPs. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use. Determine which securities are right for you based on your investment objectives, risk tolerance, financial situation and other individual factors and re-evaluate them on a periodic basis.

Before investing in any exchange traded product, you should consider its investment objective, risks, charges and expenses. Contact Fidelity for a prospectus, offering circular or, if available, a summary prospectus containing this information. Read it carefully.